FDA orders warning labels for GLP‑1 weight‑loss drugs over rare eye disease

The U.S. Food and Drug Administration has issued a new warning about a rare eye condition that can cause sudden, permanent blindness in patients taking GLP‑1 medications used for weight loss.

The agency said it will require all GLP‑1 drugs to carry information about the risk of nonarteritic anterior ischemic optic neuropathy, known as NAION, on their warning labels.

According to The Guardian, the rule applies to Novo Nordisk’s Ozempic and Wegovy, Eli Lilly’s Mounjaro and Zepbound, and Sanofi’s Soliqua.

NAION is a rare disorder that can lead to rapid loss of vision. By adding the label, the FDA aims to make patients and prescribers aware of the potential danger.

The step comes as GLP‑1 drugs have become widely prescribed for obesity and diabetes, prompting regulators to tighten safety information.

Why it matters

The warning alerts users of popular weight‑loss drugs to a rare but serious risk of permanent blindness, prompting clinicians to consider eye‑health monitoring.

Key details

Location

United States · Americas

Reported by

The Guardian

First reported

11 Nov 2026, 01:48 IST

Key names

GLP-, FDA, US Food, Drug Administration

Section

Health

Sources

This is an independent summary. Read the full, original reporting from the publisher:

• The GuardianFDA warns of rare eye condition causing blindness from GLP-1 weight loss medications 11 Nov, 01:48

Read the full story at The Guardian ↗

Spotted an error? Request a correction · How this summary was produced